RegulatoryOfficial

Estonia authorises Bioveta's BioBos BTV 3 bluetongue vaccine for one year

🇪🇪 Ravimiamet · Tue 27 Oct 2026

Ravimiamet's October 2026 overview of veterinary approvals lists one product: Bioveta's BioBos BTV 3 injectable suspension, authorised on 26 October with a one-year validity.

The Estonian State Agency of Medicines (Ravimiamet) has published its overview of veterinary marketing authorisations registered in October 2026. The item is dated 27 October and lists a single product.

According to the agency, BioBos BTV 3 was granted a marketing authorisation on 26 October 2026. The holder is Bioveta a.s. The authorisation is valid for one year, a shorter term than the one the listing implies for a standard approval.

The entry gives the active substance as bluetongue virus (described in Estonian as sheep catarrhal fever virus) and the pharmaceutical form as a suspension for injection. Two ATC vet codes are listed, QI02AA08 and QI04AA02. The marketing authorisation number is 1239526. The strength column is blank in the published text.

The overview does not give target species, indications, the legal basis for the authorisation or the reason for the one-year term. It also does not say whether the authorisation is national or issued through another procedure.

What it means for your team

  • Market-access teams tracking Estonia should record BioBos BTV 3 (Bioveta a.s., authorisation no. 1239526) as a new national veterinary authorisation.
  • The one-year validity means the renewal or follow-up date needs to be diarised. The source does not explain the reason for the short term.
  • Teams needing species, indication or legal-basis details should consult the full product documentation, as the overview does not include them.

Official source: Ravimiamet ↗

Article written by VigiEye from the official source (Ravimiamet). AI-assisted; check the source before acting.

More Regulatory All →